Healthcare Industry News: Allergan Medical
News Release - April 27, 2010
KYTHERA Biopharmaceuticals Appoints Industry Veteran as Vice President, Global Clinical OperationsPierre J.G. Corin, MS, Joins KYTHERA
LOS ANGELES--(HSMN NewsFeed)--KYTHERA Biopharmaceuticals, Inc. ("KYTHERA") announced today the appointment of Pierre J.G. Corin, MS, as Vice President, Global Clinical Operations.
Pierre brings more than 20 years of experience in clinical operations and management of large international trials, including specific expertise in aesthetic medicine. Pierre joins KYTHERA from Allergan Medical where he was the Director of Clinical Development and was responsible for the Silicone Breast Implant Follow-Up Study (BIFS). The BIFS study is the largest multinational post-approval study of its kind.
Prior to Allergan Medical, Pierre held senior positions at several multinational Contract Research Organizations (CROs) including PPD, Covance, ClinTrials and Innovex.
“Pierre joins KYTHERA at a critical time to lead clinical operations as we move toward global registrational trials,” said Patricia Walker, MD, PhD, KYTHERA's Chief Medical Officer. “We are fortunate to have someone with such expertise in managing large scale, multinational trials. I am confident he will add immediate value in planning and guiding our efforts.”
Corin holds an MS from University of Liege (Belgium).
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA is a privately-held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market. The aesthetic market is characterized by an aging population, increasing discretionary income and an evolution of patient preference towards care that focuses on quality of life. The Company uses the tools of biotechnology to develop prescription therapeutics for this emerging market. KYTHERA has a robust pipeline, with clinical programs in adipolysis, facial contouring and pigmentation modulation and research programs in photoaging, topical neuromodulation and prevention of hair loss.
For more information about KYTHERA, please visit the Company’s web site at www.kytherabiopharma.com.
Source: KYTHERA Biopharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.